Navigation Links
FDA Agrees to Amend Dendreon's Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
Date:3/12/2008

se 3 studies (D9901 and D9902A), Dendreon would expect to achieve the pre-specified criterion for significance and would amend the BLA submission with the FDA based on these interim results.

"The amendment of the SPA allows us to accelerate the expected timing of our final results by a year while maintaining comparable power for the study," said Mitchell H. Gold, president and chief executive officer of Dendreon. "Our commitment to helping patients with prostate cancer is unwavering, and we remain focused on providing the necessary data to the FDA as quickly as possible to enable us to bring PROVENGE to the men in need of a new treatment option."

Conference Call Information

Dendreon will host a conference call tomorrow at 8:00 a.m. PT, 11:00 a.m. ET. To access the live call, dial 1-877-548-7901 (domestic) or +1-719-325-4844 (international). The call will also be audio webcast and will be available from the Company's website at http://www.dendreon.com under the "Investor/Webcasts and Presentations" section. A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-888-203-1112 or +1-719-457-0820 for international callers; the conference ID number is 5074038. The replay will be available from 7:30 pm ET on Thursday, March 13 until 11:59 pm ET on Saturday, March 15. In addition the webcast will be archived for on-demand listening for 30 days at http://www.dendreon.com.

About IMPACT Study Design

The IMPACT trial is a randomized, double blind, placebo controlled Phase 3 study, which enrolled just over 500 men with metastatic, androgen independent prostate cancer with a primary endpoint of overall survival.

About Prostate Cancer

Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than o
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. FDA Agrees to Review Cimzia(R) File for the Treatment of Rheumatoid Arthritis
2. Inverness Medical Innovations Agrees to Acquire ParadigmHealth
3. Inverness Medical Innovations Agrees to Acquire Panbio Ltd.
4. Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
5. Mylan Announces Amendment to Bystolic(TM) (Nebivolol) Agreement
6. Neurobiological Technologies Announces Amendment of License and Cooperation Agreement with Merz Pharmaceuticals and Childrens Hospital
7. Barr Confirms Patent Challenge of Namenda(R) Tablets, 5mg & 10mg
8. ExonHit and bioMerieux Amend Their Strategic Partnership
9. Halozyme Therapeutics Amends Stockholder Rights Plan
10. Beanstalk Capital Ltd. and iCo Therapeutics Inc. amend arrangement agreement
11. Genmab Amends HuMax-CD4 Pivotal Study in CTCL
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Dallas, Texas (PRWEB) November 26, 2014 ... Bifluoride Industry” is a professional and in-depth research ... Ammonium Bifluoride information, like its definition, classification, application, ... overview. This report covers the international market analysis, ... (such as the US, Europe, Asia, China, Japan ...
(Date:11/26/2014)... 26, 2014 The Alliance for ... survey of European physicians at the "1 ST ... Biological Therapies" at the Spanish Ministry of Health, ... EuropaBio and the Spanish Bioindustry Association (ASEBIO), included ... from Spanish oncology and rheumatology societies, representatives from ...
(Date:11/26/2014)... November 25, 2014 SonaCare Medical, ... Ultrasound (HIFU) devices, recently participated in the American ... Mass 360° .” Key opinion leaders in urology ... related to small renal masses while attendees had ... ablative technologies in hands-on labs. Attendees at the ...
(Date:11/26/2014)... (PRWEB) November 25, 2014 Miles Holder, ... joined the Graphel Carbon Products team as Sales/Marketing Manager. ... marketing, and customer service for the graphite industry. , ... to our team,” stated Dave Trinkley, VP of Market ... wide range of experience in the graphite industry, along ...
Breaking Biology Technology:Ammonium Bifluoride Market International Analysis of Manufacturing, Technology & Trends Now at ReportsnReports.com 2Ammonium Bifluoride Market International Analysis of Manufacturing, Technology & Trends Now at ReportsnReports.com 3ASBM Presents European Physicians Survey at Spanish Ministry of Health 2SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 2SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 3Miles Holder Joins Graphel Corporation as Sales/Marketing Manager 2
... 2011 Sigma-Aldrich® (NASDAQ: SIAL ) ... Directors declared a quarterly cash dividend of $.18 per share. ... of record on December 1, 2011. The Board ... the Company,s repurchase authorization.  This action brings the total authorization ...
... Star Line Group , U.S. Advisors ... reinsurance program in response to the final regulations published recently ... "We recognize the unique requirements of organizations that want ... need to moderate their downside risk in an affordable fashion," ...
... Nov. 8, 2011 ACCESS PHARMACEUTICALS, INC. ... proprietary drug-delivery platforms to develop treatments in areas of ... it has entered into an agreement with a major ... CobOral technology for the targeted delivery of RNAi therapeutics. ...
Cached Biology Technology:Sigma-Aldrich (NASDAQ: SIAL) Declares Quarterly Dividend. 2New ACO Reinsurance Program Launched by Star Line Group, U.S. Advisors and Ascendent Care 2Access Pharmaceuticals Signs Agreement for CobaCyte® and CobOral® in RNAi Therapeutic Delivery 2Access Pharmaceuticals Signs Agreement for CobaCyte® and CobOral® in RNAi Therapeutic Delivery 3
(Date:11/4/2014)... VILNIUS, Lithuania , Nov. 4, 2014 /PRNewswire/ ... identification technologies, today announced that the latest version ... place in the Ongoing MINEX evaluation ... interoperability of fingerprint algorithms using the INCITS 378 ... a mandatory requirement in public tenders in ...
(Date:11/3/2014)... A University of Colorado Cancer Center study ... Academy of Sciences describes the activity of a ... Interleukin 37 or IL-37. It has been known to ... in the adaptive immune system: IL-37 inhibits the ability ... antigens. , "Knowing this mechanism that underlies IL-37,s effect ...
(Date:11/3/2014)... and preterm birth are linked to increased risk for ... the American College of Rheumatology (ACR) journal, Arthritis ... and pre-term babies were not at greater risk of ... According to the ACR, 27 million Americans over the ... of OA range from mild to severe and include ...
Breaking Biology News(10 mins):Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 2Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 3PNAS: From HIV to cancer, IL-37 regulates immune system 2Preterm, low birth-weight babies may need new hips in adulthood 2
... discovery by Monash University scientists could see humble cotton ... devices capable of detecting diseases such as kidney failure ... have used ordinary cotton thread and sewing needles to ... is the size of a postage stamp. Microfluidic ...
... look identicalnot to mention drabto the human eye. But that,s ... essentially colorblind. A new study published online on February 25th ... that the fish can easily tell one species from another ... on their faces. Although scientists have long known that ...
... that a microbe called Trichodesmium , a member of ... budget. New research results reported on-line today in a ... may have to share its nitrogen-fixing throne: two others ... UCYN-A and Crocosphaera watsonii , are also abundant in ...
Cached Biology News:How long is a piece of thread? Long enough to save a life 2Fish can recognize a face based on UV pattern alone 2More than 1: Long-reigning microbe controlling ocean nitrogen shares the throne 2
Borosilicate Glass. Certified for use with the Beacon 2000 Systems, 1,000 tubes/case...
Whole blood is collected from mice (Swiss Webster, 8-10 weeks old,either sex) and processed within 45 minutes of collection. The complement is then filtered and pooled on ice, bottled and stored at -...
... technology incorporating the sophisticated DirectDrive architecture ... new Varian NMR System is undeniably ... ,The Varian NMR System features parallel ... channel, providing pulse sequence programming power ...
... Immunogen : Recombinant human ... 5mg/ml BSA, 0.15M NaCl, 0.05% ... of glycerol to 30% Quality ... on acid extracts of murine ...
Biology Products: